InterCure (INCR)
(Delayed Data from NSDQ)
$1.87 USD
-0.01 (-0.27%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.86 -0.01 (-0.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INCR 1.87 -0.01(-0.27%)
Will INCR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for INCR
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
InterCure reports 1H results
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
Rising High: SNDL announces successful bid to acquire Indiva
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany